Cerebral palsy medications given to adults may not match needs

Some medications are seen as a "fix-all" solution, not addressing the root problem

5:00 AM

Author | Valerie Goodwin

drawing on orange background of colorful pills floating with body parts in them in pain
Justine Ross, Michigan Medicine

Pain and symptom management are important parts of caring for adults living with cerebral palsy. 

However, these patients are often treated with medications that may not align with the underlying type of symptom they’re experiencing.

This disconnect can lead to adults with cerebral palsy being prescribed medications that aren’t the correct treatment for the source of their concerns, creating patterns of people taking drugs that are unnecessary and could potentially worsen their health or create more complications down the line.

SEE ALSO: Changing the definition of cerebral palsy

Examining the most common patterns of pain and symptom management strategies among adults living with cerebral palsy, University of Michigan Health professor of physical medicine and rehabilitation, Mark Peterson, Ph.D., M.S., FACSM, was able to observe if there are any differences by pain phenotype or co-occurring neurodevelopmental disorders and the medication that’s prescribed to treat them.

Looking at medication and therapy prescription estimates for pain and cerebral palsy symptom management, Peterson and team identified the most common pharmaceutical pain and symptom management interventions.

These included (from most prescribed to least prescribed) antiepileptics, antidepressants, benzodiazepines, nonsteroidal anti-inflammatories, non-perioperative opioids, antipsychotics, muscle relaxants, irritable bowel syndrome-specific drugs, clonidine, anticholinergics and botulinum toxin A injections.

Physical and occupational therapy, two primary interventions for pain and symptom management among children with CP, were prescribed for only 41% of the adult participants in the cohort.

SEE ALSO: Cerebral palsy doesn't cause death in adults, so why is it still listed as an underlying cause?

Unfortunately, not much has been known historically about the overall national prescribing patterns to treat pain and related symptoms in cerebral palsy, which could lead to adverse reactions.

“One of the most alarming discoveries from this research was the evidence that individuals with mixed pain phenotype presentations had a considerably greater pattern of prescriptions ranging from 60% for muscle relaxants to 80% for non-operative opioids,” said Peterson.

Peterson stresses that it’s important to use proper screening tools to better understand not only the type and/or origin of the presenting pain, but also how widespread the pain is.

“It’s vital to understand the potential links between opioid exposures and common symptoms or comorbidities of cerebral palsy, particularly respiratory disorders, psychiatric disorders, bowel disorders and fall-related fractures,” he said.

SEE ALSO: Better understanding cerebral palsy pain types could lead to better treatment

As Peterson continues to work to examine the ways pain and other symptoms can be properly addressed and treated for people with cerebral palsy, his team has created an overview with recommendations for pain treatment in adults with cerebral palsy. This is in conjunction with a large international project working to create the first clinical practice guideline for adults with cerebral palsy.

Additional authors: Heidi Haapala, M.D., Mary Schmidt, D.O., and Edward A. Hurvitz, M.D., from the Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI. Michael O’Leary, B.S., and Kathryn Ashbaugh, B.S., from the Institute for Healthcare Policy and Innovation, Michigan Medicine, University of Michigan, Ann Arbor, MI. Meil Kamdar, M.A., from the Institute for Healthcare Policy and Innovation, Michigan Medicine, University of Michigan, Ann Arbor, MI, the Center for Population Health Sciences, Stanford University, Stanford, CA, and the Cecil H. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC.

Funding/disclosures: This research was developed in part under a grant from the National Institutes of Health (grant no: #1R21DE032584-01).

Paper cited: “Medication and Therapy Profiles for Pain and Symptom Management Among Adults With Cerebral Palsy,” Mayo Clinic Proceedings: Innovations, Quality & Outcomes. DOI: 10.1016/j.mayocpiqo.2025100597

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week.

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows.


More Articles About:

Basic Science and Laboratory Research Health Care Quality chronic pain Health Screenings Cerebral Palsy
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Mark D Peterson, PhD

Mark D Peterson

Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Two people in medical scrubs are in a blurred hospital setting. In the foreground, hands are holding a digital tablet.
Health Lab

Digital alerts support timely treatment decisions of critically ill cardiac patients

Well-designed alerts for critically ill cardiac patients can change what happens at the bedside, according to new Michigan Medicine research.
Michelle Hastings, Ph.D. and lab member look at molecule on computer screen.
News Release

$3.9 million NIH grant to fuel U-M effort to develop first targeted therapy for fatal childhood brain disorder

A team led by Dr. Michelle Hastings will advance a new RNA-based medicine for the most common form of CLN3 Batten disease toward clinical trials
Father comforts sick child
News Release

15 years of data will help uncover how flu spreads—and how to reduce its impact

$14.2-million NIH award to University of Michigan funds research to untangle intricacies of person-to-person flu transmission—and reduce illness, deaths, economic losses
A stylized digital image of an X-ray of a human skeleton superimposed on a strand of DNA
Health Lab

Bigger data reveals the second, third and fourth switches controlling a gene

A University of Michigan study reveals the untapped potential of the NIH-sponsored Trans-Omics for Precision Medicine, or TOPMed, program.
layers of skin pink to yellow
Health Lab

Study outlines a new framework for direct cell reprogramming

In a new paper published in the journal iScience, Lindsey Muir, Ph.D. and her lab at Michigan Medicine propose a framework for direct cell reprogramming.
cells close up blue and green background microscope
Health Lab

Engineered nanoparticles sensitize gliomas to radiotherapy

University of Michigan researchers discovered a new pathway that sensitizes mIDH1 gliomas to radiation in human and mouse mIDH1 glioma cells and mouse models, paving the way for phase 1 clinical trials in humans